+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
COX-2 Selective NSAIDs Market by Application, End-User, Drug Type, Dosage Form - Global Forecast 2025-2030- Product Image
COX-2 Selective NSAIDs Market by Application, End-User, Drug Type, Dosage Form - Global Forecast 2025-2030- Product Image
Sale

COX-2 Selective NSAIDs Market by Application, End-User, Drug Type, Dosage Form - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 191 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6011575
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The COX-2 Selective NSAIDs Market grew from USD 7.83 billion in 2023 to USD 8.19 billion in 2024. It is expected to continue growing at a CAGR of 5.42%, reaching USD 11.33 billion by 2030.

COX-2 selective NSAIDs, also known as COX-2 inhibitors, are a class of non-steroidal anti-inflammatory drugs designed to target cyclooxygenase-2 (COX-2) enzymes responsible for inflammation and pain while sparing COX-1 enzymes that help maintain the normal lining of the stomach. The necessity of COX-2 inhibitors arises from the demand for treatments offering pain relief with reduced gastrointestinal side effects compared to traditional NSAIDs. They are primarily applied in managing conditions like osteoarthritis, rheumatoid arthritis, and acute pain. End-use sectors include hospitals, clinics, and sometimes over-the-counter sales, expanding their accessibility. Market growth is significantly driven by the increasing prevalence of chronic diseases that require pain management and a growing aging population. The development of safer and more effective anti-inflammatory drugs also presents vibrant opportunities. However, the market faces substantial challenges, such as stringent regulatory policies and the cardiovascular risks associated with certain COX-2 inhibitors, which limit their widespread adoption. Recent advances in drug delivery systems and molecular targeting promise new avenues for innovation, including the development of novel formulations that minimize side effects and maximize therapeutic benefits. Research is being touted towards pinpointing more precise biomarkers for inflammatory diseases, which could lead to customized drug regimens, thereby driving market expansion. Despite its potential, the COX-2 selective NSAID market's growth is hampered by ongoing safety concerns, especially related to long-term cardiovascular risk, demanding rigorous post-marketing surveillance. As for potential areas of innovation, integrating COX-2 inhibitors with complementary therapies or pursuing advancements in biodegradable delivery mechanisms can spur business growth. The market remains dynamic, with opportunities primarily steered by advancements in personalized medicine and an increasing emphasis on balancing efficacy with safety. Emphasizing strategic alliances and R&D endeavors focused on enhancing drug profiles could empower stakeholders to capitalize effectively on burgeoning market demands.

Understanding Market Dynamics in the COX-2 Selective NSAIDs Market

The COX-2 Selective NSAIDs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing prevalence of chronic inflammatory diseases driving demand for COX-2 selective NSAIDs
    • Rising awareness among healthcare professionals about benefits of selective COX-2 inhibitors
    • Growing geriatric population leading to higher incidence of osteoarthritis and rheumatoid arthritis
    • Advancements in pharmaceutical research enhancing efficacy and reducing side effects of COX-2 inhibitors
  • Market Restraints
    • Strict advertising regulations restricting promotional activities for COX-2 selective NSAIDs
    • Public perception and awareness issues affecting market acceptance of COX-2 selective NSAIDs
  • Market Opportunities
    • Development of novel COX-2 selective NSAIDs with improved efficacy and safety profiles
    • Expansion into emerging markets with high prevalence of chronic inflammatory conditions
    • Leveraging digital marketing strategies to increase brand awareness and patient engagement
  • Market Challenges
    • Intellectual property concerns and patent expirations affecting market exclusivity for COX-2 selective NSAIDs
    • Competition from non-selective NSAIDs and their impact on market penetration of COX-2 selective NSAIDs

Exploring Porter’s Five Forces for the COX-2 Selective NSAIDs Market

Porter’s Five Forces framework further strengthens the insights of the COX-2 Selective NSAIDs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the COX-2 Selective NSAIDs Market

External macro-environmental factors deeply influence the performance of the COX-2 Selective NSAIDs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the COX-2 Selective NSAIDs Market

The COX-2 Selective NSAIDs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the COX-2 Selective NSAIDs Market

The COX-2 Selective NSAIDs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the COX-2 Selective NSAIDs Market

The COX-2 Selective NSAIDs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the COX-2 Selective NSAIDs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alkem Laboratories, Amgen Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim GmbH, Dr. Reddy’s Laboratories, Eli Lilly and Company, GlaxoSmithKline plc, Hikma Pharmaceuticals plc, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and Zydus Cadila.

Market Segmentation & Coverage

This research report categorizes the COX-2 Selective NSAIDs Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Application
    • Cardiology
      • Myocardial Infarction
      • Stroke
    • Oncology
      • Breast Cancer
      • Colorectal Cancer
      • Lung Cancer
      • Prostate Cancer
    • Pain Management
      • Chronic Back Pain
      • Osteoarthritis
      • Postoperative Pain
      • Rheumatoid Arthritis
  • End-User
    • Clinics
    • Homecare Settings
    • Hospitals
    • Research Institutes
  • Drug Type
    • Celecoxib
    • Etoricoxib
    • Rofecoxib
    • Valdecoxib
  • Dosage Form
    • Capsules
    • Injectables
    • Suspensions
    • Tablets
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of chronic inflammatory diseases driving demand for COX-2 selective NSAIDs
5.1.1.2. Rising awareness among healthcare professionals about benefits of selective COX-2 inhibitors
5.1.1.3. Growing geriatric population leading to higher incidence of osteoarthritis and rheumatoid arthritis
5.1.1.4. Advancements in pharmaceutical research enhancing efficacy and reducing side effects of COX-2 inhibitors
5.1.2. Restraints
5.1.2.1. Strict advertising regulations restricting promotional activities for COX-2 selective NSAIDs
5.1.2.2. Public perception and awareness issues affecting market acceptance of COX-2 selective NSAIDs
5.1.3. Opportunities
5.1.3.1. Development of novel COX-2 selective NSAIDs with improved efficacy and safety profiles
5.1.3.2. Expansion into emerging markets with high prevalence of chronic inflammatory conditions
5.1.3.3. Leveraging digital marketing strategies to increase brand awareness and patient engagement
5.1.4. Challenges
5.1.4.1. Intellectual property concerns and patent expirations affecting market exclusivity for COX-2 selective NSAIDs
5.1.4.2. Competition from non-selective NSAIDs and their impact on market penetration of COX-2 selective NSAIDs
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. COX-2 Selective NSAIDs Market, by Application
6.1. Introduction
6.2. Cardiology
6.2.1. Myocardial Infarction
6.2.2. Stroke
6.3. Oncology
6.3.1. Breast Cancer
6.3.2. Colorectal Cancer
6.3.3. Lung Cancer
6.3.4. Prostate Cancer
6.4. Pain Management
6.4.1. Chronic Back Pain
6.4.2. Osteoarthritis
6.4.3. Postoperative Pain
6.4.4. Rheumatoid Arthritis
7. COX-2 Selective NSAIDs Market, by End-User
7.1. Introduction
7.2. Clinics
7.3. Homecare Settings
7.4. Hospitals
7.5. Research Institutes
8. COX-2 Selective NSAIDs Market, by Drug Type
8.1. Introduction
8.2. Celecoxib
8.3. Etoricoxib
8.4. Rofecoxib
8.5. Valdecoxib
9. COX-2 Selective NSAIDs Market, by Dosage Form
9.1. Introduction
9.2. Capsules
9.3. Injectables
9.4. Suspensions
9.5. Tablets
10. Americas COX-2 Selective NSAIDs Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific COX-2 Selective NSAIDs Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa COX-2 Selective NSAIDs Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation
LIST OF FIGURES
FIGURE 1. COX-2 SELECTIVE NSAIDS MARKET RESEARCH PROCESS
FIGURE 2. COX-2 SELECTIVE NSAIDS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 7. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 9. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 11. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
FIGURE 13. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. COX-2 SELECTIVE NSAIDS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. COX-2 SELECTIVE NSAIDS MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
TABLE 1. COX-2 SELECTIVE NSAIDS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. COX-2 SELECTIVE NSAIDS MARKET DYNAMICS
TABLE 7. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY STROKE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CHRONIC BACK PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY POSTOPERATIVE PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CELECOXIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ETORICOXIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROFECOXIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY VALDECOXIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 61. CANADA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. CANADA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 63. CANADA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 64. CANADA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 65. CANADA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. CANADA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 67. CANADA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 68. MEXICO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 69. MEXICO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 70. MEXICO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 71. MEXICO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 72. MEXICO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. MEXICO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 74. MEXICO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 83. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 85. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 86. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 87. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 88. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 89. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 90. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 91. AUSTRALIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. AUSTRALIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 93. AUSTRALIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 94. AUSTRALIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 95. AUSTRALIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 96. AUSTRALIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 97. AUSTRALIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 98. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 100. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 101. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 102. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 104. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 105. INDIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 106. INDIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 107. INDIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 108. INDIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 109. INDIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 110. INDIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 111. INDIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 112. INDONESIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 113. INDONESIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 114. INDONESIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 115. INDONESIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 116. INDONESIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 117. INDONESIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 118. INDONESIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 119. JAPAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. JAPAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 121. JAPAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 122. JAPAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 123. JAPAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 124. JAPAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 125. JAPAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 126. MALAYSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. MALAYSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 128. MALAYSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 129. MALAYSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 130. MALAYSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 131. MALAYSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 132. MALAYSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 133. PHILIPPINES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. PHILIPPINES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 135. PHILIPPINES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 136. PHILIPPINES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 137. PHILIPPINES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 138. PHILIPPINES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 139. PHILIPPINES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 140. SINGAPORE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. SINGAPORE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 142. SINGAPORE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 143. SINGAPORE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 144. SINGAPORE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 145. SINGAPORE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 146. SINGAPORE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 147. SOUTH KOREA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. SOUTH KOREA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 149. SOUTH KOREA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 150. SOUTH KOREA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 151. SOUTH KOREA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 152. SOUTH KOREA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 153. SOUTH KOREA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 154. TAIWAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 155. TAIWAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 156. TAIWAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 157. TAIWAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 158. TAIWAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 159. TAIWAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 160. TAIWAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 161. THAILAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 162. THAILAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 163. THAILAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 164. THAILAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 165. THAILAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 166. THAILAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 167. THAILAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 168. VIETNAM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 169. VIETNAM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 170. VIETNAM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 171. VIETNAM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 172. VIETNAM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 173. VIETNAM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 174. VIETNAM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 183. DENMARK COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 184. DENMARK COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 185. DENMARK COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 186. DENMARK COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 187. DENMARK COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 188. DENMARK COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 189. DENMARK COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 190. EGYPT COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 191. EGYPT COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 192. EGYPT COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 193. EGYPT COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 194. EGYPT COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 195. EGYPT COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 196. EGYPT COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 197. FINLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 198. FINLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 199. FINLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 200. FINLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 201. FINLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 202. FINLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 203. FINLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 204. FRANCE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 205. FRANCE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 206. FRANCE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 207. FRANCE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 208. FRANCE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 209. FRANCE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 210. FRANCE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 211. GERMANY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 212. GERMANY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 213. GERMANY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 214. GERMANY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 215. GERMANY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 216. GERMANY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 217. GERMANY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 218. ISRAEL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 219. ISRAEL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 220. ISRAEL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 221. ISRAEL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 222. ISRAEL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 223. ISRAEL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 224. ISRAEL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 225. ITALY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 226. ITALY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 227. ITALY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 228. ITALY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 229. ITALY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 230. ITALY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 231. ITALY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 232. NETHERLANDS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 233. NETHERLANDS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 234. NETHERLANDS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 235. NETHERLANDS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 237. NETHERLANDS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 238. NETHERLANDS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 243. NIGERIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 244. NIGERIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 245. NIGERIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 246. NORWAY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 247. NORWAY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 248. NORWAY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 249. NORWAY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 250. NORWAY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 251. NORWAY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 252. NORWAY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 253. POLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 254. POLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 255. POLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 256. POLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 257. POLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 258. POLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 259. POLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 260. QATAR COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 261. QATAR COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 262. QATAR COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 263. QATAR COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 264. QATAR COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 265. QATAR COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 266. QATAR COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 267. RUSSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 268. RUSSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 269. RUSSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 270. RUSSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 271. RUSSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 272. RUSSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 273. RUSSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 274. SAUDI ARABIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 276. SAUDI ARABIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 278. SAUDI ARABIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 280. SAUDI ARABIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 282. SOUTH AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 284. SOUTH AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 286. SOUTH AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 288. SPAIN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 289. SPAIN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 290. SPAIN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 291. SPAIN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 292. SPAIN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 293. SPAIN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 294. SPAIN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 295. SWEDEN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 296. SWEDEN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 297. SWEDEN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 298. SWEDEN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 299. SWEDEN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 300. SWEDEN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 301. SWEDEN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 302. SWITZERLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 303. SWITZERLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 304. SWITZERLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 305. SWITZERLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 306. SWITZERLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 307. SWITZERLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 308. SWITZERLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 309. TURKEY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 310. TURKEY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 311. TURKEY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 312. TURKEY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 313. TURKEY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 314. TURKEY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 315. TURKEY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 316. UNITED ARAB EMIRATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 317. UNITED ARAB EMIRATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 318. UNITED ARAB EMIRATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 319. UNITED ARAB EMIRATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 320. UNITED ARAB EMIRATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 322. UNITED ARAB EMIRATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 323. UNITED KINGDOM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 324. UNITED KINGDOM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 325. UNITED KINGDOM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 326. UNITED KINGDOM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 327. UNITED KINGDOM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 328. UNITED KINGDOM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 329. UNITED KINGDOM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 330. COX-2 SELECTIVE NSAIDS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 331. COX-2 SELECTIVE NSAIDS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the COX-2 Selective NSAIDs market, which are profiled in this report, include:
  • AbbVie Inc.
  • Alkem Laboratories
  • Amgen Inc.
  • AstraZeneca
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Dr. Reddy’s Laboratories
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals plc
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Cadila

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages191
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 8.19 Billion
Forecasted Market Value ( USD ) by 2030 $ 11.33 Billion
Compound Annual Growth Rate5.4%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Report and Forecast 2024-2032 - Product Image

Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From
Migraine Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (Ditans, NSAIDs), By Route Of Administration (Oral, Injectable), By Treatment, By Age Group, By Availability, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Migraine Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (Ditans, NSAIDs), By Route Of Administration (Oral, Injectable), By Treatment, By Age Group, By Availability, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 159 Pages
  • Global
From
Non-steroidal Anti-inflammatory Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Non-steroidal Anti-inflammatory Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 95 Pages
  • Global
From
Non-Steroidal Anti-Inflammatory Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Non-Steroidal Anti-Inflammatory Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Drug Pipelines
  • 150 Pages
  • Global
From
US Non-postoperative Acute Pain - Market Insights, Epidemiology, and Market Forecast - 2032 - Product Image

US Non-postoperative Acute Pain - Market Insights, Epidemiology, and Market Forecast - 2032

  • Report
  • 129 Pages
  • United States
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.